Dr. Peter Zhou of University of Kentucky Markey Cancer Center has determined that a key enzyme is missing from triple-negative breast cancer. This may lead to insight on a treatment option.
Researchers found that in triple-negative breast cancer cells, transcription factor complex Snail-G9a-Ddmt1 is over-expressed, and the enzyme 1,6bisphosphate (FBP1) is inhibited. This results in glucose coming in and "feeding" the tumor.
Identifying this reaction in triple-negative breast cancer is important because it is the most deadly of breast cancers. It occurs mostly in younger women.
“These findings present significant insights regarding the development and progression of triple-negative breast cancer,” says Dr Zhou, associate professor of molecular and cellular biochemistry at UK. “They indicate that targeting the metabolic alteration will lead to an effective approach for treating this deadly disease.”
For the full article, visit http://www.aalatimes.com/2013/03/06/study-shows-key-enzyme-missing-from-aggressive-form-of-breast-cancer/.
Researchers found that in triple-negative breast cancer cells, transcription factor complex Snail-G9a-Ddmt1 is over-expressed, and the enzyme 1,6bisphosphate (FBP1) is inhibited. This results in glucose coming in and "feeding" the tumor.
Identifying this reaction in triple-negative breast cancer is important because it is the most deadly of breast cancers. It occurs mostly in younger women.
“These findings present significant insights regarding the development and progression of triple-negative breast cancer,” says Dr Zhou, associate professor of molecular and cellular biochemistry at UK. “They indicate that targeting the metabolic alteration will lead to an effective approach for treating this deadly disease.”
For the full article, visit http://www.aalatimes.com/2013/03/06/study-shows-key-enzyme-missing-from-aggressive-form-of-breast-cancer/.
No comments:
Post a Comment